Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.42 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.42 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.42 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.42 |
| ▸ | CBFB | Q13951 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4418275 | 0.78 | GLS (0.58) | L3MBTL1HTTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL14009931 | 0.73 | GLS (0.50) | L3MBTL1KDM4EMAPTPTK2GLS | |
| SCHEMBL28583200 | 0.71 | — | — | |
| SCHEMBL8934616 | 0.71 | KDM4E (0.47) | L3MBTL1HTTSMN1; SMN2KDM4EMAPT | |
| SCHEMBL316074 | 0.71 | L3MBTL1 (0.52) | L3MBTL1SMN1; SMN2KDM4EKMT2ANPC1 | |
| SCHEMBL25681597 | 0.69 | GLS (0.50) | L3MBTL1HTTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL22529510 | 0.68 | GLS (0.49) | L3MBTL1HTTSMN1; SMN2KDM4EMAPT | |
| SCHEMBL10480584 | 0.68 | PTK2 (0.50) | L3MBTL1HTTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL19924514 | 0.68 | GLS (0.49) | L3MBTL1HTTSMN1; SMN2KDM4EMAPT | |
| SCHEMBL11296558 | 0.68 | L3MBTL1 (0.44) | L3MBTL1HTTSMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017189866-A1 | POLYMYXIN ANALOGS USEFUL AS ANTIBIOTIC POTENTIATORS | SPERO OPCO (US) | 2017-11-02 | — | — | WO | claimed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | claimed |
| WO-2017189866-A1 | POLYMYXIN ANALOGS USEFUL AS ANTIBIOTIC POTENTIATORS | SPERO OPCO (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
| US-4385181-A | CHAMICAL INTERMEDIATES FOR CEPHALOSPORINS | RHONE POULENC INDUSTRIES (FR) | 1983-05-24 | — | — | US | disclosed |
| US-4307116-A | BACTERICIDES | RHONE-POULENC INDUSTRIES (FR) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | L3MBTL1 1776/4885HTT 1948/4885SMN1; SMN2 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.